Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 5, 2025

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, …

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in the LCA5 gene Administration of OPGx-LCA5 by …

Hydreight Technologies Appoints Dr. Roebuck As a Director of the Company
VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) ("Hydreight" or the "Company"), a North American, fully integrated, mobile clinical network of nurses, doctors, and pharmacy …

Study Shows Large Improvements in Long COVID Symptoms and Return to Work
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Researchers at the University of Alabama at Birmingham (UAB) have identified what is believed to be the first intervention found in a randomized controlled trial to show large and very large improvements in …

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscle …

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress
Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today issued the …

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
-Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date- SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company …

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, today announced that …

Algernon Announces Warrant Extension
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company …

ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model
Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the …

AAFA Calls on Congress to Restore Lifesaving National Asthma Control Program
Washington, DC, May 05, 2025 (GLOBE NEWSWIRE) -- On May 6, 2025 – World Asthma Day – the Asthma and Allergy Foundation of America (AAFA) will visit the U.S. Capitol to call on Congress to protect the 28 million people in the U.S. with asthma and restore …

Vyvamind Under Review: Does Vyvamind Work? Best Adderall Alternative Nootropic Supplement
Albany, New York, May 05, 2025 (GLOBE NEWSWIRE) -- VyvaMind is marketed as a neurostimulant available without a prescription, aimed at high-performing adults who need extended periods of intense concentration regardless of the time of day. This includes …

BioNTech ernennt Ramón Zapata zum neuen Finanzvorstand
Mainz, Deutschland, 5. Mai 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Ramón Zapata-Gomez mit Wirkung zum 1. Juli 2025 zum Finanzvorstand (Chief Financial Officer, „CFO“) …

BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, …

Best Premature Ejaculation Pills: Treatment, Meaning, How to Treat, What is Premature Ejaculation, Early Ejaculation Problem, How To Avoid Quick Discharge Of Sperm, Causes (Performer 8)
Glasgow, May 05, 2025 (GLOBE NEWSWIRE) -- 2025: Introduction Performer 8 is a reliable dietary supplement designed to enhance testosterone levels and improve male sexual health. Many men have reported positive outcomes after using it. If you're over 18 and …

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
Pipeline: Delivered on our commitment to a more focused R…

Best Protein Powders For Muscle Gain: New Report Reveals Which Protein Powders Actually Work.
New York, May 05, 2025 (GLOBE NEWSWIRE) -- WhatBest, a trusted platform for expert product research and testing, has released its highly anticipated guide to the best protein powders for building muscle. The newly published report is designed to help …

Inventiva obtient la deuxième tranche de 116 millions d'euros de son financement structuré d'un montant maximum de 348 millions d'euros
Le financement intervient à la suite de la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et à la suite de l’atteinte d’autres conditions préalables. Daix (France), New York City (New York …

Smith+Nephew stellt sein CORI™ Surgical System in chirurgischen Kliniken in Deutschland, Österreich und der Schweiz vor
Die Roadshow „CORI on Tour“ zeigt die neuesten Fortschritte in der robotergestützten Chirurgie für Knie- und Hüftgelenkersatz Smith+Nephew (LSE:SN, NYSE:SNN), das globale Medizintechnikunternehmen, kündigt heute eine monatelange Roadshow durch …

NANOBIOTIX PRÉSENTE LES RÉSULTATS COMPLETS DE L’ÉTUDE DE PHASE 1 ÉVALUANT JNJ-1900 (NBTXR3) DANS LE CANCER DU PANCREAS
Les résultats ont démontré un bon profil de tolérance, une faisabilité d’injection satisfaisante, ainsi que des signaux cliniques encourageants en matière d‘activité antitumorale chez des patients atteints d’un cancer du pancréas localement avancé ou à la …